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Abstract
Microtubule stabilizers are some of the most successful drugs used in the treatment of adult solid
tumors and yet the molecular events responsible for their antimitotic actions are not well defined.
The mitotic events initiated by three structurally and biologically diverse microtubule stabilizers;
taccalonolide AJ, laulimalide/fijianolide B and paclitaxel were studied. These microtubule
stabilizers cause the formation of aberrant, but structurally distinct mitotic spindles leading to the
hypothesis that they differentially affect mitotic signaling. Each microtubule stabilizer initiated
different patterns of expression of key mitotic signaling proteins. Taccalonolide AJ causes
centrosome separation and disjunction failure to a much greater extent than paclitaxel or
laulimalide, which is consistent with the distinct defects in expression and activation of Plk1 and
Eg5 caused by each stabilizer. Localization studies revealed that TPX2 and Aurora A are
associated with each spindle aster formed by each stabilizer. This suggests a common mechanism
of aster formation. However, taccalonolide AJ also causes pericentrin accumulation on every
spindle aster. The presence of pericentrin at every spindle aster initiated by taccalonolide AJ might
facilitate the maintenance and stability of the highly focused asters formed by this stabilizer.
Laulimalide and paclitaxel cause completely different patterns of expression and activation of
these proteins, as well as phenotypically different spindle phenotypes. Delineating how diverse
microtubule stabilizers affect mitotic signaling pathways could identify key proteins involved in
modulating sensitivity and resistance to the antimitotic actions of these compounds.
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1. Introduction
Microtubules are key components of the cytoskeleton and are important for numerous
cellular processes including intracellular transport, maintenance of cell shape and separation
of the sister chromatids. Because of their roles in mitosis and other cellular processes,
microtubules are an attractive and proven target for anticancer drugs. Microtubule targeting
agents continue to be useful in the treatment of adult and pediatric cancers. These agents are
classified as microtubule stabilizers or destabilizers based on their effects on interphase
microtubules at relatively high concentrations. Paclitaxel, the first microtubule stabilizer
identified, binds within the taxane site on the interior surface of the microtubule, where it
strengthens protofilament interactions leading to microtubule stabilization (1, 2). In addition
to the taxanes, the epothilones, discodermolide, and dictyostatin bind within the taxane site
but with subtly different orientations (3). Laulimalide and peloruside A, bind to a second
microtubule stabilizer site that is located on the exterior surface of microtubules (3–7). All
microtubule stabilizers suppress microtubule dynamics at low antiproliferative
concentrations (8).
The taccalonolides are a class of chemically and mechanistically distinct microtubule
stabilizing agents (9, 10). Consistent with the effects of all other microtubule stabilizers, the
taccalonolides cause the appearance of thick bundles of microtubules in interphase cells and
the formation of aberrant mitotic spindles that lead to mitotic arrest and initiation of
apoptosis (10). The taccalonolides are potent antitumor agents in vivo with efficacy superior
or equal to paclitaxel in multiple murine models (10, 11). A direct interaction of
taccalonolides A and E with microtubules was not detected (12) but the newly identified,
highly potent taccalonolides, AF and AJ, bind directly to tubulin/microtubules and stimulate
tubulin polymerization (13). Their binding site is under investigation.
While the phenotypic effects of the taccalonolides are similar to other microtubule
stabilizers, they are also subtly different. The taccalonolides initiate short, thick microtubule
bundles throughout the cytoplasm, while paclitaxel initiates long bundles of microtubules
that appear to nucleate from the centrosome (10). Additionally, the taccalonolides initiate
microtubule bundling at much lower concentrations relative to the IC50 for inhibition of
proliferation as compared to paclitaxel (10). Together, these data support the hypothesis that
the taccalonolides have cellular effects somewhat different than other microtubule
stabilizers.
Mitosis involves a series of highly coordinated events that are temporally and spatially
regulated leading to the formation of a bipolar mitotic spindle. Extensive research has
examined the effects of paclitaxel on cellular stress and apoptotic pathways. However, the
molecular events leading from stabilizer-initiated suppression of microtubule dynamics to
aberrant mitotic spindle assembly and mitotic arrest have not been defined. The aim of this
study was to begin to identify how structurally diverse microtubule stabilizers alter mitotic
signaling to cause the severe mitotic defects that precede mitotic arrest and ultimately, cell
death. Identification of these signaling pathways will help identify key partners in the
response to microtubule stabilizers that might be altered in some cancers precluding a robust
response to microtubule stabilizers and potentially clinical drug resistance. Our studies
demonstrate that chemically diverse microtubule stabilizers initiate substantially different
effects on mitotic signaling pathways and begin to identify potential biomarkers that might
predict sensitivity or resistance to microtubule stabilizing agents.
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2. Materials and methods
2.1 Materials
Paclitaxel was purchased from Sigma-Aldrich (St. Louis, MO). Taccalonolide AJ was semi-
synthesized as previously described (13). Ethanol (Sigma-Aldrich, St. Louis, MO) was used
to solubilize each drug and as the vehicle control. Laulimalide/fijianolide B was isolated as
previously described (7).
2.2 Cell culture
HeLa cells were obtained directly from American Type Culture Collection (Manassas, VA).
They were maintained in Basal Medium Eagle (Sigma-Aldrich, St. Louis, MO) with Earle’s
salts supplemented with 10% fetal bovine serum (Hyclone, South Logan, Utah) and 50 μg/
ml gentamicin (Invitrogen, Grand Island, NY). Cells were maintained at 37°C in a
humidified incubator with 5% CO2.
2.3 Whole cell lysate preparation and Western blotting
HeLa cells were synchronized by double thymidine block as described previously (14).
Immediately after release, drug or vehicle was added. The cells were treated with the lowest
concentration that caused maximal G2/M accumulation; for paclitaxel, 12.5 nM, for
taccalonolide AJ, 16 nM, and for laulimalide, 17.5 nM. At specific time points after drug
addition, cells were harvested by scraping and centrifugation and divided into aliquots. One
aliquot was used to make whole cell lysates and the second was used for evaluating cell
cycle distribution. Cells were lysed using cell extraction buffer (Invitrogen, Grand Island,
NY) supplemented with protease inhibitors. Protein concentrations were measured and equal
amounts of proteins were separated by SDS-PAGE, transferred to a PVDF membrane and
probed overnight at 4°C for specific proteins using antibodies for: Aurora A, P-Aurora A
Thr 288, P-Lamin A/C, P-Histone H3 Ser 10, and P-Tacc3 Ser 558 (Cell Signaling, Danvers,
MA); Actin (Sigma-Aldrich, St. Louis, MO); TPX2 and P-Eg5 Thr 927 (Biolegend, San
Diego, CA); Tacc3, Plk1, and P-Plk1 Thr 210 (Epitomics, Burlingame, CA). The signal was
visualized with Amersham ECL Plus (GE Health Care, Piscataway, NJ) in a Geliance
(Perkin Elmer, Waltham, MA) imaging system. The signal intensity was quantitated using
GeneTools (Syngene, Frederick, MD) by normalizing the signal to the time zero lysate,
which was the same for all treatment groups.
2.4 Flow cytometry
The second aliquot of cells harvested was spun at 2000 rpm for 10 min. The supernatant was
discarded and the pellet resuspended in Krishan’s reagent (Sigma-Aldrich, St. Louis, MO)
containing propidium iodide and RNAse A. Cells were analyzed for DNA content using a
FACSCalibur (BD Biosciences, San Jose, CA).
2.5 Indirect immunofluorescence
HeLa cells were plated on glass coverslips, allowed to grow for 24 h and then treated with
the compounds for 18 h and fixed with cold methanol. The pertinent structures were
visualized with the following antibodies: Rabbit β-tubulin (Abcam, Cambridge, MA);
mouse β-tubulin (Sigma-Aldrich, St. Louis, MO); γ-tubulin (Sigma-Aldrich, St. Louis,
MO), pericentrin (Abcam, Cambridge, MA) Aurora A (Cell Signaling, Danvers, MA), TPX2
(Biolegend, San Diego, CA) Nek2 and Rootletin (Novus Biologicals, Littleton, CO) and the
DNA was visualized using DAPI. The centrin antibody was a generous gift from Dr.
Salisbury, Mayo Clinic, Rochester, MN. For centrosome separation or disjunction, a
minimum of 100 mitotic cells were counted per coverslip and the numbers from a minimum
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of three independent experiments were averaged. Cells were classified as having
centrosomes that failed to separate if individual centrosomes were touching.
3. Results
3.1 Mitotic spindle phenotypes
Initial studies indicated that the mitotic spindles formed in the presence of the taccalonolides
were different from those seen with other microtubule stabilizers (10, 13, 15). The effects of
taccalonolide AJ were evaluated in HeLa cells and compared to the effects of paclitaxel and
laulimalide. The chemical structures of these microtubule stabilizers are shown in Fig 1A.
The relative potencies of these compounds are similar, with IC50 values in HeLa of 2–4 nM
and G2/M arrest concentrations of 12.5–17.5 nM. The cellular effects of microtubule
stabilizers depend on concentration and thus the concentration used for each stabilizer was
the lowest concentration that caused maximal G2/M arrest. This concentration was carefully
defined for each compound using flow cytometry. These concentrations were used
throughout the current studies to compare the effects of these microtubule stabilizers on
mitotic spindle structures and on mitotic signaling.
Normal bipolar mitotic spindles were observed in vehicle-treated cells (Fig 1B). In contrast,
taccalonolide AJ initiated the formation of multiple mitotic spindle asters, typically 5–9 per
cell (Fig 1B) that were compact and located throughout the cytoplasm. Phenotypically
different mitotic spindle asters were formed in laulimalide-treated cells, with a
distinguishing feature of circular mitotic spindles with a central region devoid of β-tubulin
(Fig 1B). This distinctive laulimalide spindle phenotype has been noted in other cell types
with laulimalide (6) or laulimalide analogs (16). Other mitotic spindle structures are also
observed in laulimalide-treated cells, and these consisted of 2–5 distinct, yet slightly diffuse
spindle asters (Fig 1B). Paclitaxel initiated abnormal mitotic spindles containing 2–3 diffuse
spindle asters that appeared more poorly organized (Fig 1B). The differences in both spindle
morphology and the number of mitotic spindle asters in cells treated with taccalonolide AJ
in comparison to laulimalide or paclitaxel led us to hypothesize that the mechanisms of
spindle formation might be different among these microtubule stabilizers, possibly in
response to different mitotic signaling defects.
3.2 Taccalonolide AJ leads to severe and distinct centrosomal defects
The numerous and focused nature of the spindle asters formed by taccalonolide AJ
suggested the possibility that these aberrant asters could be induced by centrosome
amplification. Taccalonolide AJ-treated cells contained only two γ-tubulin foci, associated
with only two of the many spindle asters (Fig 2A), suggesting that there was no centrosome
amplification or fragmentation. This was also true for the asters formed in the presence of
laulimalide or paclitaxel where two γ-tubulin foci were seen. Other components of the
centrosome including centrin and pericentrin were also evaluated. In vehicle-treated cells the
normal co-localization of pericentrin to each of the centrioles was observed (data not
shown). Taccalonolide AJ-treated cells also contained two pairs of centrin signals, similar to
γ-tubulin. This same phenotype was also seen in laulimalide and paclitaxel-treated cells (Fig
2C). In contrast, multiple pericentrin foci (Fig 2C) were observed in taccalonolide AJ-
treated cells but not in paclitaxel or laulimalide-treated cells. Two large pericentrin foci
always co-localized with γ-tubulin at the centrosomes (Fig 2E), while less intense
pericentrin staining was found at every other aberrant spindle aster (Fig 2D). Laulimalide
and paclitaxel did not cause extra pericentrin foci as evidenced by the presence of only two
pericentrin foci that co-localized with γ-tubulin (Fig 2E) and only two of the spindle asters
(Fig 2D).
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In the process of evaluating γ-tubulin, centrin and pericentrin localization, we observed a
significant population of taccalonolide AJ-treated cells that had entered mitosis with
unseparated centrosomes. Unlike vehicle-treated cells, 64% of taccalonolide AJ-treated cells
had centrosomes that had not separated prior to mitosis (Fig 2A). It is important to note that
none of these cells with unseparated centrosomes had monopolar spindles (Fig 2B). In
contrast, only 21% of paclitaxel- treated cells showed centrosome separation defects (Fig
2B). Laulimalide was intermediate with 41% of cells having failed centrosome separation.
These results highlight major differences among the stabilizers with regard to the
organization of mitotic spindle aster formation and suggest functional defects in centrosome
maturation and disjunction, especially with taccalonolide AJ.
The taccalonolides have a higher propensity for microtubule bundling at low
antiproliferative concentrations as compared to paclitaxel (9). It was possible that the
centrosome defects observed represent a continuum and that the more severe defects seen
with taccalonolide AJ could occur with higher concentrations of laulimalide or paclitaxel.
The concentration dependent effects of the stabilizers on centrosomal defects were
evaluated. A dose dependent increase in the percentage of cells that failed to separate their
centrosomes, similar to the effects of taccalonolide AJ (Fig 2F), was observed with higher
concentrations of laulimalide and paclitaxel. At a concentration of 500 nM paclitaxel or
laulimalide, the majority of cells failed to separate their centrosomes. In contrast, the
centrosome separation defects were maximal with taccalonolide AJ at the G2/M arrest
concentration (16 nM) (Fig 2B and F). Consistent with the centrosome separation defects,
higher concentrations of laulimalide or paclitaxel increased the number of spindle asters
observed in mitotic cells. Surprisingly, although both centrosome separation defects and
mitotic spindle asters increased with higher concentrations of laulimalide or paclitaxel, the
localization of pericentrin did not change with higher concentrations of these stabilizers and
remained different from that seen with taccalonolide AJ (data not shown).
3.3 Taccalonolide AJ causes centrosome disjunction defects
Further studies were conducted to evaluate the mechanisms by which taccalonolide AJ
inhibited centrosome separation. Prior to mitosis, the centrosomes are held together by
linker proteins, C-Nap-1 and Rootletin. During centrosome disjunction, Nek2 kinase
phosphorylates these proteins resulting in their displacement from the centrosome, allowing
for separation. Centrosome disjunction defects in drug-treated cells were investigated by
evaluating the localization of Nek2 and Rootletin in interphase cells since centrosomes
normally separate prior to mitotic entry. Vehicle-treated cells positive for Nek2 showed two
patterns (Fig 3A). A total of 57% of the cells had Nek2 foci that were separate and 43% had
Nek2 foci that appeared to be touching (Fig 3A and B). This same pattern was seen in cells
treated with laulimalide (47% together, 53% apart) or paclitaxel (44% together, 56% apart).
In contrast, 92% of taccalonolide AJ-treated cells had Nek2 foci that were touching (Fig 3A
and B). This was corroborated by Rootletin localization. 60% of vehicle-treated cells had
Rootletin positive centrosomes that were still together and 40% were separate. With
taccalonolide AJ, 97% of cells had Rootletin foci that were touching (Fig 3C and D). In
contrast, laulimalide or paclitaxel-treated cells showed Rootletin localization (Fig 3C and D)
that matched that of Nek2 and did not differ substantially from the vehicle control. These
data suggest that taccalonolide AJ-initiated defects in centrosome separation are due in part
to inhibition of centrosome disjunction and that these effects are unique to the taccalonolides
as they were not observed with paclitaxel or laulimalide.
3.4 Microtubule stabilizers lead to changes in the expression of Plk1 and Eg5
The centrosomal defects initiated by taccalonolide AJ and to a lesser extent laulimalide
suggested the possibility that they disrupt Plk1. This kinase plays important roles in
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centrosome maturation and separation and it regulates centrosome disjunction by indirectly
activating Nek2. Additionally, Plk1 targets the microtubule motor Eg5 to the centrosome
where Eg5 facilitates centrosome separation. As vehicle-treated cells moved into mitosis
Plk1 expression increased and was maximal at 6 h. Plk1 is activated by phosphorylation,
which began 5 h after release and was maintained until the vehicle-treated cells moved back
into G1. In cells treated with taccalonolide AJ, the levels of total Plk1 were diminished and
expression was delayed with maximal accumulation at 8 h. Phosphorylated Plk1 was also
delayed in taccalonolide AJ-treated cells. The initial increase in Plk1 activation was not
apparent until 8 h where it increased further during mitotic arrest (Fig 4 A and B). In stark
contrast, laulimalide caused early Plk1 expression as compared to control, and an early
increase in Plk1 activation with phosphorylation levels rising 3 h earlier than that seen in
vehicle-treated cells. Paclitaxel-treated cells exhibited lower expression of Plk1 as cells
moved into mitosis with lower levels of Plk1 than was seen with the other microtubule
stabilizers or with vehicle. Additionally, the phosphorylation of Plk1 in paclitaxel-treated
cells was substantially delayed. These data indicate substantial differences among the
stabilizers in both the timing and levels of Plk1 expression and activation. Laulimalide
initiated early expression and activation and paclitaxel and taccalonolide AJ caused a delay
in expression and activation as cells moved into mitosis. Later during the prolonged mitotic
arrest, the levels of phospho-Plk1 were highest with paclitaxel and taccalonolide AJ.
Inhibition of Eg5 causes the formation of monopolar mitotic spindles due to centrosome
separation failure. Additionally, phosphorylation of Eg5 on Thr 927 by Cdk1 supports Eg5’s
association with microtubules, thereby facilitating centrosome separation. Taccalonolide AJ
initiated higher levels of phospho-Eg5 than were observed with vehicle, paclitaxel or
laulimalide (Fig 4A and D). In contrast, laulimalide and paclitaxel, caused a slight delay in
Eg5 phosphorylation, and the levels were much lower than those seen with taccalonolide AJ
and resemble vehicle (Fig 4A and D). With paclitaxel, a late increase in levels of phospho-
Eg5 was observed at 9–10 h similar to the levels that occurred with taccalonolide AJ (Fig 4
and D), but higher than was obtained with laulimalide. These results again show distinct
molecular differences among the microtubule stabilizers.
3.5 Effects of microtubule stabilizers on Aurora A expression
The microtubule stabilizer induced changes in Plk1 suggested possible defects in Aurora A
signaling since Plk1 targets Aurora A to the centrosome. In taccalonolide AJ-treated cells,
the expression of Aurora A increased at the same time as in vehicle-treated cells (Fig 5A and
B). However, 8 h after release, Aurora A levels in taccalonolide AJ-treated cells were higher
than was observed with vehicle and protein levels accumulated further 8–10 h after release.
In contrast, laulimalide initiated premature expression of Aurora A beginning 2 h after
release and these higher levels were maintained through 9 h. (Fig 5 A and B). Surprisingly,
with paclitaxel, the levels of Aurora A did not increase as the cells moved into G2/M at 5–6
h, and did not begin to increase until 8 h after release. The cumulative levels of Aurora A in
paclitaxel-treated cells were much lower 8–10 h after release as compared to cells treated
with laulimalide or taccalonolide AJ.
Aurora A is phosphorylated on multiple sites, including Thr 288 which controls its kinase
activity (17, 18). Consistent with the protein levels of Aurora A, phosphorylation of Thr 288
increased as vehicle-treated cells entered mitosis and decreased as they exited into G1 (Fig
5A and C). Levels of phospho-Aurora A in taccalonolide AJ-treated cells were similar to
control. Laulimalide initiated early and higher levels of activated Aurora A, consistent with
total protein accumulation. Although the levels of Aurora A were lower in paclitaxel-treated
cells, phospho-Aurora A levels were similar to the controls as the cells moved into mitosis.
In comparing the drugs, the total levels of phospho-Aurora A were highest in laulimalide-
treated cells throughout the time course.
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Aurora A is targeted to the spindle poles by TPX2 where it facilitates Aurora A
autophosphorylation and protects it from dephosphorylation by PP1, thereby preventing the
proteosomal degradation of Aurora A (19). TPX2 expression increased in vehicle-treated
cells as cells moved into mitosis at 5 h and then diminished as cells exited mitosis (Fig 5A
and D). Taccalonolide AJ caused a similar pattern of TPX2 expression with levels slightly
higher than control at all time points with a time-dependent accumulation 8–10 h during
mitotic arrest. In laulimalide-treated cells, the same pattern of expression seen with Aurora
A was observed; the levels of TPX2 increased early, 2 h after release, were maintained from
2–9 h, and began to diminish slightly by 10 h. This differs substantially from the pattern
seen with vehicle or taccalonolide AJ (Fig 5A and D). Consistent with the effects of
paclitaxel on Aurora A levels, paclitaxel also initiated different effects on TPX2 expression.
Paclitaxel did not cause a major change in the levels of TPX2 as cells entered mitosis, and
only a small increase was seen at 8 h, indicating slower accumulation of TPX2 as compared
with vehicle, taccalonolide AJ or laulimalide. Additionally, levels of TPX2 were lower in
paclitaxel-treated cells as compared to vehicle from 5–9 h, especially when compared to
TPX2 expression in the presence of the other microtubule stabilizers.
The effects of the microtubule stabilizers on Tacc3, a downstream substrate of Aurora A
were evaluated as a measure of Aurora A activity. In vehicle-treated cells, the levels of
Tacc3 increased as the cells moved into mitosis and levels of phosphorylated Tacc3
increased at 8 h with maximal levels obtained at 9 h. Taccalonolide AJ had no major effects
on total Tacc3, but higher levels of phospho-Tacc3 were observed as compared to control as
cells moved into mitosis. In laulimalide-treated cells the levels of total Tacc3 increased as
the cells moved into mitosis and total protein levels diminished slightly by 10 h from the
maximal levels that occurred at 5–9 h. Laulimalide initiated an increase in the levels of
phospho-Tacc3 occurring within 4 h, substantially earlier than was observed with vehicle.
Paclitaxel caused a different pattern of Tacc3 and phospho-Tacc3 expression. There was an
early accumulation of total Tacc3 at 4 h, but by 9 and 10 h higher levels than any other
treatment group were maintained. Phospho-Tacc3 was not observed until 8 h post release, in
contrast to the earlier accumulation that occurred in vehicle, taccalonolide AJ and
laulimalide-treated cells. Overall, these changes are consistent with our findings on the
effects of these drugs on Plk1 expression and activation and further validate our hypothesis
that these stabilizers cause distinct and specific defects in these mitotic pathways.
3.6 Differential localization of TPX2 and Aurora A
Due to the defects caused by these microtubule stabilizers on the expression of Aurora A
and associated proteins; we evaluated their effects on the localization of Aurora A and its
activating partner TPX2. In vehicle-treated cells (Fig 6A) Aurora A was localized to both
spindle poles, with staining observed along the microtubules close to the poles. Aurora A
staining was similar after treatment with any of the microtubule stabilizers. Aurora A was
associated with each of the spindle asters with brighter staining apparent at 2 asters (Fig
6A), which were shown to co-localize with λ-tubulin at the centrosome (Fig 6B). While
each aster contained Aurora A, there was more Aurora A associated with the λ-tubulin
containing spindle asters (Fig 6B).
The effects of the drugs on the localization of TPX2, which targets Aurora A to
microtubules, were evaluated. In vehicle-treated cells, TPX2 was localized along the
microtubules of the mitotic spindle (Fig 6C). Aurora A was also co-localized with TPX2
only close to the centrosome. Surprisingly, in taccalonolide AJ, laulimalide and paclitaxel-
treated cells, unlike Aurora A localization, TPX2 was equally localized to each mitotic aster
(Fig 6C). This was confirmed by co-staining TPX2 and Aurora A (Fig 6D). The differential
localization of TPX2 and Aurora A in response to the microtubule stabilizers highlights
some of the similarities shared among these agents. These results also suggest a constant
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difference between centrosomal nucleated asters and those that lack normal centrosomal
components. Even though the expression and activation of central mitotic proteins were
differentially affected the localization patterns did not differ between the stabilizers.
4. Discussion
The ability of microtubule stabilizers to inhibit mitosis leading to initiation of apoptosis has
been known for decades. However, the molecular mechanisms leading from microtubule
stabilizer-initiated suppression of microtubule dynamics to initiation of apoptosis are still
not well defined. In this study we begin to elucidate the signaling defects initiated by 3
chemically diverse microtubule stabilizers. This is early work highlighting the similarities
and differences in the ability of taccalonolide AJ, laulimalide or paclitaxel to alter the
expression, activation and appropriate localization of central mitotic kinases including Plk1,
Aurora A and TPX2. Additionally, our data show that these compounds cause very different
effects on the mitotic signaling cascades that we suggest contribute to the distinct aberrant
mitotic spindle structures.
Unlike paclitaxel and laulimalide, the majority of cells treated with taccalonolide AJ failed
to complete centrosome separation. It is possible that the lower levels of Plk1 and the 3 h
delay in Plk1 phosphorylation caused by taccalonolide AJ contributes to centrosome
separation and disjunction failures. This is consistent with studies that have shown that
inhibition of Plk1 prevents centrosomal targeting of Eg5 and activation of Nek2 (20, 21).
Nek2 activation is necessary for the phosphorylation of its target linker proteins, C-Nap1
and Rootletin, which causes their displacement from the centrosome thus allowing
centrosome disjunction (22–25). Plk1 and Eg5 regulate centrosome separation and either
pathway can compensate for the other (20). The high Eg5 activity observed in the
taccalonolide AJ-treated cells may be a mechanism by which cells are attempting to
overcome the lack of normal Plk1 activity. However, the increased levels of phosphorylated
Eg5 caused by taccalonolide AJ were unexpected considering the centrosomal phenotypes
we observed, because high Eg5 activity can support centrosome separation even in the
absence of Plk1 activity (20). Our results suggest that the multiple defects initiated by
taccalonolide AJ cannot be overcome to allow centrosome separation and disjunction.
Taccalonolide AJ is the only stabilizer of the three that causes dramatic interphase
microtubule bundling at the minimum concentration that causes full G2/M arrest (Fig 3A,
C). A role for microtubules in centrosome separation has been established (20) and it is
possible that the microtubule stabilization initiated by taccalonolide AJ contributes to
inhibition of centrosome separation. We have evidence of this because higher concentrations
of paclitaxel or laulimalide that initiate microtubule bundling also cause more centrosome
separation defects (Fig 2F).
Diverse mitotic phenotypes have been observed with different concentrations of paclitaxel
(26). An important question to address was whether the severe defects in centrosome
separation observed with low concentrations of taccalonolide AJ could also be obtained with
higher concentrations of laulimalide and paclitaxel. Our results with laulimalide and
paclitaxel, at concentrations from 50–500 nM, show a dose dependent increase in
centrosome separation failure (Fig 2F) and a shift in mitotic aster morphology to closely
resemble the phenotypes seen with the lower, G2/M arresting concentrations of
taccalonolide AJ. In contrast, higher concentrations of taccalonolide AJ did not change the
incidence of centrosome separation defects, highlighting the fact that the taccalonolides
produce these effects at much lower relative concentrations than paclitaxel or laulimalide. It
is interesting to speculate that these concentration dependent differences represent a
continuum of effects related to the ability of these microtubule stabilizers to disrupt normal
microtubule structures. Our previous studies showed that the taccalonolides caused
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microtubule bundling defects at low, antiproliferative concentrations and that higher relative
concentrations of paclitaxel are needed to initiate these effects (9). Therefore, the differences
in centrosome separation and spindle aster defects observed among the drugs at the G2/M
arrest concentrations might relate to whether they cause microtubule reorganization and are
not unique to one class of microtubule stabilizers. In contrast, no change in pericentrin
localization to the additional asters was seen with higher concentrations of either paclitaxel
or laulimalide even though the spindle asters resembled taccalonolide AJ induced asters.
This suggests that the taccalonolides are unique in their ability to alter centrosome integrity.
One mechanism by which multiple spindle asters form is through centrosome fragmentation.
If this were the case the multipolar asters would be expected to contain normal centrosomal
components. This was not the case in cells treated with taccalonolide AJ, paclitaxel or
laulimalide, suggesting that these asters are not formed by centrosome fragmentation.
However, taccalonolide AJ was unique among the stabilizers evaluated in that it caused
aberrant spindle asters that all contained pericentrin but lacked additional centrosomal
components. Phosphorylation of pericentrin by Plk1 leads to the recruitment of γ-tubulin
ring complexes to the centrosomes (27). Our data suggest that while pericentrin localizes to
each aberrant aster, it is not likely that Plk1 is phosphorylating it because of the lack of
additional centrosomal components at these aberrant asters. This is consistent with the
delayed Plk1 expression and activation caused by taccalonolide AJ.
Our results show that taccalonolide AJ, paclitaxel and laulimalide cause distinct changes in
the expression of Aurora A and are consistent with their effects on Plk1 and TPX2
expression. In addition to being mitotic cofactors, studies show that Aurora A can directly
phosphorylate and activate Plk1 (28). The pattern of Aurora A expression in laulimalide-
treated cells matches that seen with Plk1 and TPX2. Moreover, the early activation of
Aurora A caused by laulimalide is consistent with the early phosphorylation of Plk1
observed, suggesting appropriate co-localization of these kinases. The activation of Plk1 was
most delayed in paclitaxel-treated cells, consistent with late expression and activation of
Aurora A, and also the possibility of inappropriate co-localization. In contrast, taccalonolide
AJ did not dramatically change the timing of Aurora A expression. Not unexpectedly, with
taccalonolide AJ the levels and timing of Plk1 phosphorylation mirrors the activation of
Aurora A. The coordinated timing of Aurora A expression and Plk1 activation suggests that
they are localized together.
Aurora A amplification has been shown to confer resistance to paclitaxel and studies have
shown that its down regulation can sensitize cells to paclitaxel treatment (29). Our data
suggest that one of the mechanisms by which paclitaxel inhibits mitotic progression is
mediated by inhibition of Aurora A expression and activation. This provides a mechanism
by which overexpression of Aurora A can confer resistance to paclitaxel. Based on our
results it is interesting to speculate that Aurora A amplification might not lead to resistance
to laulimalide or taccalonolide AJ, but further studies will be needed to evaluate this
possibility.
Tacc3 recruits XMAP215 to the spindle, which aids in the stabilization and focusing of the
mitotic spindle (30, 31). Consistent with a reduction in Aurora A levels, a delay and
reduction in the levels of phospho-Tacc3 was also observed with paclitaxel. This could
result in an inability to focus paclitaxel-induced aberrant asters, leading to diffuse asters. In
contrast, both taccalonolide AJ and laulimalide caused much higher levels of phospho-Tacc3
and mitotic spindle asters that are much more focused and compact. It is possible that the
increased phospho-Tacc3 facilitates maintenance and focusing of mitotic asters.
Additionally, recent studies demonstrated a kinase-independent role for Aurora A in the
formation and stabilization of centrosome-independent spindle asters (32). It is possible that
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the laulimalide-induced increase in total Aurora A levels contributes to the distinct mitotic
structures observed with laulimalide. In taccalonolide AJ-treated cells, and more so with
paclitaxel, the delay in expression of Aurora A might contribute to the formation of different
mitotic aster structures.
Various studies have shown that in the absence of centrosomes TPX2, Aurora A and another
microtubule associated protein, NuMA, can induce the formation of mitotic spindle poles in
the vicinity of the chromosomes (33, 34). Our data show that TPX2 and Aurora A are
present in each spindle aster formed by all three of the microtubule stabilizers (Fig 6). This
is consistent with their established role in acentrosomal spindle formation and suggests a
shared mechanism among these microtubule stabilizers. Taccalonolide AJ is unique,
however, in that pericentrin is also seen localized to each taccalonolide AJ-induced spindle
aster. We propose that the presence of the combination of TPX2, Aurora A and pericentrin
leads to the maintenance and stability of the highly focused spindle asters that occur only
with taccalonolide AJ.
Another possibility for the differences observed in both number and morphology of the
mitotic spindle asters generated in response to laulimalide and paclitaxel at the G2/M arrest
concentration may be related to their distinct and non-overlapping binding sites on tubulin.
Recent studies show that while paclitaxel stabilizes longitudinal interactions between α- and
β-tubulin dimers, laulimalide can strongly stabilize the lateral interactions between adjacent
protofilaments (3). Additionally this study showed that overall, microtubule stabilizers
strongly stabilize specific sites on tubulin that have been shown to overlap with the binding
sites of a variety of microtubule associated proteins and motors (3). The potential for a
distinct binding site for taccalonolide AJ could also lead to differential effects on
microtubules, leading ultimately to distinct spindle phenotypes at the G2/M arrest
concentration.
In this study we begin to lay a framework that shows that chemically diverse microtubule
stabilizers alter mitotic signaling pathways in different ways. While microtubule stabilizers
have been used in the clinic for over two decades, it is not yet possible to predict which
patients will respond. In fact, studies have shown that there is variability not only among
different cancer cell types but also within cells of the cell line or tumor (35, 36). While it is
not yet possible to identify definitive biomarkers for patient response to these agents, this
work begins to outline which pathways are differentially affected by these compounds.
Further work on these findings could identify proteins that confer sensitivity or resistance
and potentially new combinations of agents that could provide synergistic anticancer effects.
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Figure 1. Mitotic spindle defects caused by chemically distinct microtubule stabilizers
(A) Chemical structures of microtubule stabilizers used in this study. (B) HeLa cells were
treated with vehicle (ethanol), taccalonolide AJ, laulimalide, or paclitaxel for 18 hours.
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Figure 2. Taccalonolide AJ causes centrosomal defects
HeLa cells were treated with vehicle, taccalonolide AJ, laulimalide or paclitaxel for 18 h.
(A) Co-localization of β-tubulin, γ-tubulin and pericentrin. White arrows indicate cells
expanded in the inset. (B) Quantification of (A). Mitotic cells were counted and scored as
containing either separated or unseparated centrosomes. Each bar graph represents the mean
from an average of at least 3 independent experiments with standard error of the mean. (C)
Co-localization of pericentrin and centrin. (D) Co-localization of pericentrin and mitotic
asters. (E) Co-localization of pericentrin and γ-tubulin. (F) Quantification as in (B) of
centrosome separation in cells treated with a range of concentrations of taccalonolide AJ,
paclitaxel or laulimalide.
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Figure 3. Taccalonolide AJ causes defects in centrosome disjunction
HeLa cells were treated with vehicle, taccalonolide AJ, laulimalide or paclitaxel for 18 h and
pertinent structures visualized by immunofluorescence. (A) Localization of microtubules
and Nek2. (B) Localization of microtubules and Rootletin (C and D). Quantitation of data
shown in (A and B). Data is from an average of at least 3 independent experiments.
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Figure 4. Microtubule stabilizers cause aberrant expression and activation of Plk1 and Eg5
(A) The effects of taccalonolide AJ, laulimalide and paclitaxel on the expression and
phosphorylation of Plk1 and Eg5 were evaluated by preparing whole cell lysates of
synchronized HeLa cells harvested 2–10 h after release. Cell cycle phase as determined by
DNA content by flow cytometry is also depicted. (B) Quantitation of western blots in (A).
Proteins were quantified by densitometry using GeneTools software. Relative values were
obtained by dividing each value by the time 0 time point.
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Figure 5. Effects of microtubule stabilizers on Aurora A and its interacting proteins
(A) The effects of taccalonolide AJ, laulimalide and paclitaxel on the expression and
activation of Aurora A were evaluated by preparing whole cell lysates of synchronized HeLa
cells harvested 2–10 h after release. Cell cycle phase as determined by DNA content using
flow cytometry is depicted. (B) Quantitation of western blots in (A). Proteins were
quantified by densitometry using GeneTools software. Relative values were obtained by
dividing each value by the time 0 time point.
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Figure 6. Microtubule stabilizers cause differential localization of TPX2 and Aurora A
HeLa cells were treated with vehicle, taccalonolide AJ, laulimalide or paclitaxel for 18 h.
Representative images of cells in mitosis were taken evaluating the localization of β-tubulin,
TPX2, γ-tubulin and Aurora A. DNA was visualized by DAPI staining. (A) Co-localization
of Aurora A with microtubules. (B) Co-localization of Aurora A with γ-tubulin at the
centrosome. (C) Co-localization of TPX2 with microtubules. (D) Co-localization of TPX2
and Aurora A.
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